STRO
USDSutro Biopharma Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$1.240
Máximo
$1.240
Mínimo
$0.832
Volume
0.06M
Fundamentos da empresa
Capitalização de mercado
108.9M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
1.76M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma from Buy to Neutral and lowers the price target from $12 to $2.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform
Citizens Capital Markets analyst Reni Benjamin downgrades Sutro Biopharma from Market Outperform to Market Perform.
Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
Wedbush analyst David Nierengarten downgrades Sutro Biopharma from Outperform to Neutral and lowers the price target from $8 to $2.
B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1
B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma from Buy to Underperform and lowers the price target from $11 to $1.
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.